DK0693933T3 - Fremgangsmåder og præparater til forsinkelse eller forebyggelse af udvikling af autoimmune sygdomme - Google Patents

Fremgangsmåder og præparater til forsinkelse eller forebyggelse af udvikling af autoimmune sygdomme

Info

Publication number
DK0693933T3
DK0693933T3 DK94914804T DK94914804T DK0693933T3 DK 0693933 T3 DK0693933 T3 DK 0693933T3 DK 94914804 T DK94914804 T DK 94914804T DK 94914804 T DK94914804 T DK 94914804T DK 0693933 T3 DK0693933 T3 DK 0693933T3
Authority
DK
Denmark
Prior art keywords
autoimmune diseases
methods
delaying
preparations
development
Prior art date
Application number
DK94914804T
Other languages
Danish (da)
English (en)
Inventor
Noel K University Of Maclaren
Andrew Muir
Original Assignee
Res Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Corp Technologies Inc filed Critical Res Corp Technologies Inc
Application granted granted Critical
Publication of DK0693933T3 publication Critical patent/DK0693933T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK94914804T 1993-04-16 1994-04-15 Fremgangsmåder og præparater til forsinkelse eller forebyggelse af udvikling af autoimmune sygdomme DK0693933T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/048,979 US5891435A (en) 1993-04-16 1993-04-16 Methods and compositions for delaying or preventing the onset of autoimmune disease
PCT/US1994/004179 WO1994023737A1 (en) 1993-04-16 1994-04-15 Methods and compositions for delaying or preventing the onset of autoimmune disease

Publications (1)

Publication Number Publication Date
DK0693933T3 true DK0693933T3 (da) 2002-10-21

Family

ID=21957455

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94914804T DK0693933T3 (da) 1993-04-16 1994-04-15 Fremgangsmåder og præparater til forsinkelse eller forebyggelse af udvikling af autoimmune sygdomme

Country Status (8)

Country Link
US (1) US5891435A (de)
EP (1) EP0693933B1 (de)
JP (1) JP3001638B2 (de)
AT (1) ATE219683T1 (de)
CA (1) CA2160543C (de)
DE (1) DE69430868T2 (de)
DK (1) DK0693933T3 (de)
WO (1) WO1994023737A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094597B1 (en) * 1994-05-20 2006-08-22 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
US5773570A (en) * 1994-05-20 1998-06-30 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
US6274549B1 (en) * 1995-06-30 2001-08-14 Novo Nordisk A/S Treatment of type 1 diabetes
US20020098194A1 (en) * 1996-03-21 2002-07-25 Paul V. Lehmann Methods for inducing immunity
JP2002500234A (ja) * 1998-01-08 2002-01-08 クリフォード ダックワース、ウィリアム インシュリン関連疾患の治療および診断の方法および組成物
WO1999056763A1 (en) * 1998-05-07 1999-11-11 The Regents Of The University Of California Use of neglected target tissue antigens in modulation of immune responses
DE60043624D1 (de) * 1999-03-12 2010-02-11 Univ R DNA-Impfung zur Behandlung von Autoimmunerkrankungen
US7030098B2 (en) 1999-03-12 2006-04-18 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for treatment of autoimmune disease
US6884785B2 (en) * 1999-06-17 2005-04-26 The Scripps Research Institute Compositions and methods for the treatment or prevention of autoimmune diabetes
US20070259007A1 (en) * 1999-10-19 2007-11-08 Kruzel Marian L Lactoferrin: an adjuvant for vaccines
AU1600401A (en) * 1999-11-12 2001-06-06 Chinese University Of Hong Kong, The Malaria vaccine
US7608683B2 (en) * 2000-08-09 2009-10-27 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
US6989146B2 (en) * 2000-08-09 2006-01-24 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
JP4264257B2 (ja) 2000-11-01 2009-05-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 熱ショックタンパク質に由来する免疫調節ペプチドとその使用
KR100729645B1 (ko) * 2000-12-29 2007-06-18 주식회사 녹십자홀딩스 글루타민산 데카르복실라제를 코딩하는 유전자가 삽입된재조합 백시니아 바이러스 및 이를 포함하는 제 1형당뇨병 예방 백신
US20030045467A1 (en) * 2001-01-05 2003-03-06 Tihamer Orban Autoantigen composition
WO2004098645A1 (en) * 2003-05-12 2004-11-18 Tolerogen, Ltd. Immunoglobulin conjugates of autoantigens and their use in the prevention of disease
WO2007127787A2 (en) * 2006-04-25 2007-11-08 Joslin Diabetes Center, Inc. Insulin autoantigen-specific regulatory cd4+ t cells
EP2054058B1 (de) 2006-08-04 2016-11-09 Beth Israel Deaconess Medical Center Pyruvatkinasehemmer und verfahren zur behandlung von erkrankungen
JP2011503232A (ja) 2007-11-20 2011-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫応答の調節
AU2011245441B2 (en) 2010-04-29 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Activators of human pyruvate kinase
EP2889039B1 (de) * 2012-08-22 2017-11-08 Regimmune Corporation Präparat zur vorbeugung oder behandlung von typ-1-diabetes
EP3033106A1 (de) * 2013-08-14 2016-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Immunadjuvanzienzusammensetzungen und verwendungen davon
US20180071376A1 (en) * 2015-03-23 2018-03-15 The Brigham And Women`S Hospital, Inc. Tolerogenic nanoparticles for treating diabetes mellitus

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2051574B (en) * 1979-05-10 1984-01-18 Kyoto Pharma Ind Adjuvant for promoting absorption of pharmacologically active substances through the rectum
US4464363A (en) * 1979-12-20 1984-08-07 Merck & Co., Inc. Ajuvants for rectal delivery of drug substances
ZA808097B (en) * 1980-12-29 1982-01-27 Lilly Co Eli Novel insulin formulations
JPS58189121A (ja) * 1982-04-30 1983-11-04 Ajinomoto Co Inc インシユリン投与賦活剤
WO1990015873A1 (en) * 1989-06-19 1990-12-27 Whitehead Institute For Biomedical Research Vector-mediated genomic insertion and expression of dna in bcg
US4789660A (en) * 1987-09-10 1988-12-06 American Home Products Corporation Insulin administration using methyl and propyl paraben
SU1624511A1 (ru) * 1989-02-14 1991-01-30 Донецкий государственный медицинский институт им.М.Горького Способ моделировани сахарного диабета
DE69031563T2 (de) * 1989-07-14 1998-02-12 Autoimmune, Inc., Lexington, Mass. Behandlung der autoimmunen uveoretinitis in menschen
ATE157257T1 (de) * 1990-03-02 1997-09-15 Autoimmune Inc Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
IL165071A (en) * 1990-03-30 2008-06-05 Autoimmune Inc A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients
US5512447A (en) * 1990-09-07 1996-04-30 The Regents Of The University Of California Methods for the diagnosis and treatment of diabetes
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
JP4242446B2 (ja) * 1992-12-03 2009-03-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 糖尿病及びスティフマン症候群の診断及び治療用改良試薬及び方法
AU1864195A (en) * 1994-03-07 1995-09-25 Auckland Uniservices Limited Prevention of diabetes

Also Published As

Publication number Publication date
JPH08508036A (ja) 1996-08-27
EP0693933A1 (de) 1996-01-31
DE69430868T2 (de) 2003-01-30
DE69430868D1 (de) 2002-08-01
US5891435A (en) 1999-04-06
EP0693933B1 (de) 2002-06-26
CA2160543A1 (en) 1994-10-27
JP3001638B2 (ja) 2000-01-24
WO1994023737A1 (en) 1994-10-27
CA2160543C (en) 2002-07-30
ATE219683T1 (de) 2002-07-15

Similar Documents

Publication Publication Date Title
DK0693933T3 (da) Fremgangsmåder og præparater til forsinkelse eller forebyggelse af udvikling af autoimmune sygdomme
DK0735893T3 (da) PAN DR-bindende peptider til styrkelse af immunsvaret
NO20101441L (no) Tolerogent peptid og farmasoytisk preparat inneholdende det samme
HUP9901186A2 (hu) Peptid-és adjuvánsalapú gyógyszerkészítmény immunmodulációra
DK0427347T3 (da) Syntetiske peptider, der kan anvendes som universelle bærere til fremstilling af immunogene konjugater, og anvendelse deraf til udvikling af syntetiske vacciner
GB2303855B (en) Helicobacter pylori antigenic protein preparation and immunoassays
WO1990006696A3 (en) Meningococcal class 1 outer-membrane protein vaccine
EP0608261A4 (de) Zusammensetzung aus einem immunreaktiven hepatitis-c-virus-polypeptid.
WO1993000365A3 (en) Hepatitis c virus (hcv) polypeptides
WO1995012677A3 (en) Immunodominant human t-cell epitopes of hepatitis c virus
HU9400350D0 (en) Retard peptides
DK395689A (da) Pharmaceutisk tilberedning til behandling af diabetes mellitus
DE69417252T2 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
HUP0100928A2 (hu) Humán inzulin B láncának részletét tartalmazó peptidanalógok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
SE8204874D0 (sv) Farmaceutiska preparat, innefattande humant insulin och humant proinsulin
OA08749A (fr) Vaccins dont l'épitope caractéristique est incorporé dans une protéine de picornavirus, notamment de poliovirus.
NO952336L (no) Insulin analoger
SE8204873L (sv) Farmaceutiska preparat, innefattande humant insulin och human c-peptid
DK148085C (da) Dipeptidet pyrglu-his(2,4-dinitrophenyl)-oh og fremgangsmaade til fremstilling af lh-rh og lh-rh-analoge peptider under anvendelse af dette dipeptid
WO1988003150A3 (fr) Preparations aminoacides contenant des peptides de n,n'-bis-l-aminoacide-l-cystine et destinees a l'administration orale et parenterale
DK0563254T3 (da) Anvendelse af IL-4 til forstærkning af immunrespons på immunogener i vacciner
IE891296L (en) A synthetic vaccine against foot and mouth disease and a¹process for the preparation thereof
KR910700259A (ko) T-세포 인지성 펩티드 변형에 의해 면역반응에 영향을 주는 방법
EP0320866A3 (de) Schützendes immundominantes Epitop in der S1-Untereinheit von Pertussistoxin